Keros Therapeutics, Inc. (KROS)

Keros Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	64.45	-187.35	-152.99	-104.68	-58.74	-45.36
Depreciation & Amortization	1.44	1.23	0.82	0.67	0.38	0.28
Loss (Gain) From Sale of Assets	-0.01	-	0	0.01	0.05	-
Stock-Based Compensation	30.59	34.87	28.76	18.68	11.72	4.1
Other Operating Activities	2.36	1.82	1.55	0.94	0.52	1.82
Change in Accounts Receivable	-3.1	-2.6	-0.14	18	-18	-
Change in Accounts Payable	-2.6	-0.25	1.61	-0.41	1.49	0.06
Change in Unearned Revenue	0.16	-	-	-	-	-
Change in Other Net Operating Assets	-8.64	-8.59	-4.12	-3.28	0.45	2.21
Operating Cash Flow	88.79	-160.87	-124.51	-70.06	-62.15	-36.89
Capital Expenditures	-1.71	-1.93	-2.46	-1.24	-1.02	-0.29
Investing Cash Flow	-1.71	-1.93	-2.46	-1.24	-1.02	-0.29
Issuance of Common Stock	75.71	392.28	179.05	120.4	28.55	259.94
Other Financing Activities	-	-0.45	-0.09	-0.09	-	-19.89
Financing Cash Flow	75.71	391.82	178.96	120.31	28.55	296.04
Net Cash Flow	162.79	229.02	51.98	49.01	-34.62	258.86
Free Cash Flow	87.08	-162.8	-126.97	-71.3	-63.17	-37.19
Free Cash Flow Margin	35.30%	-4585.91%	-84087.42%	-	-314.29%	-
Free Cash Flow Per Share	2.12	-4.35	-4.31	-2.83	-2.71	-2.40
Cash Income Tax Paid	2.25	-	-	-	-	-
Levered Free Cash Flow	49.53	-108.31	-81.25	-33.84	-39.48	-22.38
Unlevered Free Cash Flow	49.53	-108.31	-81.25	-33.84	-39.48	-22.37
Change in Working Capital	-10.04	-11.44	-2.65	14.31	-16.07	2.28

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q